Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder

REFERENCES

• Abelson, H. T., and Rabstein, L. S.. 1970. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 30:2213–2222
   PubMed Web of Science ®Google Scholar
• Bhatia, R., Wayner, E. A., McGlave, P. B., and Verfaillie, C. M.. 1994. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function. J. Clin. Investig. 94:384–391
   PubMed Web of Science ®Google Scholar
• Bovolenta, C., Driggers, P. H., Marks, M. S., Medin, J. A., Politis, A. D., Vogel, S. N., Levy, D. E., Sakaguchi, K., Appella, E., Coligan, J. E. et al. 1994. Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc. Natl. Acad. Sci. USA 91:5046–5050
   PubMed Web of Science ®Google Scholar
• Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W.. 1996. Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y
   Google Scholar
• Daley, G. Q., Van Etten, R. A., and Baltimore, D.. 1990. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the philadelphia chromosome. Science 247:824–830
   PubMed Web of Science ®Google Scholar
• Driggers, P. H., Ennist, D. L., Gleason, S. L., Mak, W. H., Marks, M. S., Levi, B. Z., Flanagan, J. R., Appella, E., and Ozato, K.. 1990. An interferon gamma-regulated protein that binds the interferon- inducible enhancer element of major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. USA 87:3743–3747
   PubMed Web of Science ®Google Scholar
• Eisenbeis, C. F., Singh, H., and Storb, U.. 1995. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev. 9:1377–1387
   PubMed Web of Science ®Google Scholar
• Eklund, E. A., Jalava, A., and Kakar, R.. 1998. PU.1, interferon regulatory factor 1, and interferon consensus sequence- binding protein cooperate to increase gp91(phox) expression. J. Biol. Chem. 273:13957–13965
   PubMed Web of Science ®Google Scholar
• Elefanty, A. G., Hariharan, I. K., and Cory, S.. 1990. bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple hematopoietic neoplasms in mice. EMBO J. 9:1069–1078
   PubMed Web of Science ®Google Scholar
• Fisher, R. C., and Scott, E. W.. 1998. Role of PU.1 in hematopoiesis. Stem Cells 16:25–37
   PubMed Web of Science ®Google Scholar
• Giese, N. A., Gabriele, L., Doherty, T. M., Klinman, D. M., Tadesse-Heath, L., Contursi, C., Epstein, S. L., Morse, H. C.III.. 1997. Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J. Exp. Med. 186:1535–1546
   PubMed Web of Science ®Google Scholar
• Gross, A. W., Zhang, X., and Ren, R.. 1999. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol. Cell. Biol. 19:6918–6928
   PubMed Web of Science ®Google Scholar
• Harada, H., Taniguchi, T., and Tanaka, N.. 1998. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie 80:641–650
   PubMed Web of Science ®Google Scholar
• Hawley, R. G., Lieu, F. H. L., Fong, A. Z. C., and Hawley, T. S.. 1995. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1:136–138
   Google Scholar
• Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., and Groffen, J.. 1990. Acute leukemia in bcr/abl transgenic mice. Nature 344:251–253
   PubMed Web of Science ®Google Scholar
• Holtschke, T., Lohler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K. P., Gabriele, L., Waring, J. F., Bachmann, M. F., Zinkernagel, R. M., Morse, H. C.III, Ozato, K., and Horak, I.. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307–317
   PubMed Web of Science ®Google Scholar
• Honda, H., Fujii, T., Takatoku, M., Mano, H., Witte, O. N., Yazaki, Y., and Hirai, H.. 1995. Expression of p210bcr-abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood 85:2853–2861
   PubMed Web of Science ®Google Scholar
• Honda, H., Oda, H., Suzuki, T., Takahashi, T., Witte, O. N., Ozawa, K., Ishikawa, T., Yazaki, Y., and Hirai, H.. 1998. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood 91:2067–2075
   PubMed Web of Science ®Google Scholar
• Kelliher, M. A., McLaughlin, J., Witte, O. N., and Rosenberg, N.. 1990. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87:6649–6653
   PubMed Web of Science ®Google Scholar
• Kelliher, M. A., Weckstein, D. J., Knott, A. G., Wortis, H. H., and Rosenberg, N.. 1993. ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice. Oncogene 8:1249–1256
   PubMedGoogle Scholar
• Kurzrock, R., Gutterman, J., and Talpaz, M.. 1988. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319:990–998
   PubMed Web of Science ®Google Scholar
• Li, S., Ilaria, R. L., Million, R. P., Daley, G. Q., and Van Etten, R. A.. 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189:1399–1412
   PubMed Web of Science ®Google Scholar
• Magram, J., Sfarra, J., Connaughton, S., Faherty, D., Warrier, R., Carvajal, D., Wu, C. Y., Stewart, C., Sarmiento, U., and Gately, M. K.. 1996. IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. Ann. N. Y. Acad. Sci. 795:60–70
   PubMed Web of Science ®Google Scholar
• Melo, J. V.. 1996. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype. Blood 88:2375–2384
   PubMed Web of Science ®Google Scholar
• Nelson, N., Kanno, Y., Hong, C., Contursi, C., Fujita, T., Fowlkes, B. J., O'Connell, E., Hu-Li, J., Paul, W. E., Jankovic, D., Sher, A. F., Coligan, J. E., Thornton, A., Appella, E., Yang, Y., and Ozato, K.. 1996. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J. Immunol. 156:3711–3720
   PubMedGoogle Scholar
• Nelson, N., Marks, M. S., Driggers, P. H., and Ozato, K.. 1993. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol. Cell. Biol. 13:588–599
   PubMed Web of Science ®Google Scholar
• Nguyen, H., Hiscott, J., and Pitha, P. M.. 1998. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 8:293–312
   Google Scholar
• Pear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., and Baltimore, D.. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780–3792
   PubMed Web of Science ®Google Scholar
• Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D.. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392–8396
   PubMed Web of Science ®Google Scholar
• Peschel, C., Aulitzky, W. E., and Huber, C.. 1996. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment—impact on treatment of myeloproliferative disorders. Leuk Lymphoma 22 (Suppl. 1):129–134
   PubMedGoogle Scholar
• Pfeffer, L. M., Dinarello, C. A., Herberman, R. B., William, B. R. G., Borden, E. C., Bordens, R., Walter, M. R., Nagabhushan, T. L., Trotta, P. P., and Pestka, S.. 1998. Biological properties of recombinant alpha-interferon: 40th anniversary of the discovery of interferons. Cancer Res. 58:2489–2499
   PubMed Web of Science ®Google Scholar
• Politis, A. D., Ozato, K., Coligan, J. E., and Vogel, S. N.. 1994. Regulation of IFN-gamma-induced nuclear expression of IFN consensus sequence binding protein in murine peritoneal macrophages. J. Immunol. 152:2270–2278
   PubMed Web of Science ®Google Scholar
• Politis, A. D., Sivo, J., Driggers, P. H., Ozato, K., and Vogel, S. N.. 1992. Modulation of interferon consensus sequence binding protein mRNA in murine peritoneal macrophages. Induction by IFN-gamma and down-regulation by IFN-alpha, dexamethasone, and protein kinase inhibitors. J. Immunol. 148:801–807
   PubMedGoogle Scholar
• Ren, R., Ye, Z., and Baltimore, D.. 1994. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev. 8:783–795
   PubMed Web of Science ®Google Scholar
• Rosenberg, N., and Baltimore, D.. 1976. A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J. Exp. Med. 143:1453–1463
   PubMed Web of Science ®Google Scholar
• Scharton-Kersten, T., Contursi, C., Masumi, A., Sher, A., and Ozato, K.. 1997. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J. Exp. Med. 186:1523–1534
   PubMedGoogle Scholar
• Schmidt, M., Nagel, S., Proba, J., Thiede, C., Ritter, M., Waring, J. F., Rosenbauer, F., Huhn, D., Wittig, B., Horak, I., and Neubauer, A.. 1998. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91:22–29
   PubMed Web of Science ®Google Scholar
• Selleri, C., Sato, T., Del Vecchio, L., Luciano, L., Barrett, A. J., Rotoli, B., Young, N. S., and Maciejewski, J. P.. 1997. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89:957–964
   PubMed Web of Science ®Google Scholar
• Sharf, R., Meraro, D., Azriel, A., Thornton, A. M., Ozato, K., Petricoin, E. F., Larner, A. C., Schaper, F., Hauser, H., and Levi, B. Z.. 1997. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J. Biol. Chem. 272:9785–9792
   PubMed Web of Science ®Google Scholar
• Talpaz, M.. 1994. Use of interferons in the treatment of chronic myeloid leukemia. Semin. Oncol. 21 (Suppl. 14):3–7
   PubMedGoogle Scholar
• Voncken, J. W., Kaartinen, V., Pattengale, P. K., Germeraad, W. T., Groffen, J., and Heisterkamp, N.. 1995. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603–4611
   PubMed Web of Science ®Google Scholar
• Weisz, A., Kirchhoff, S., and Levi, B. Z.. 1994. IFN consensus sequence binding protein (ICSBP) is a conditional repressor of IFN inducible promoters. Int. Immunol. 6:1125–1131
   PubMedGoogle Scholar
• Weisz, A., Marx, P., Sharf, R., Appella, E., Driggers, P. H., Ozato, K., and Levi, B. Z.. 1992. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J. Biol. Chem. 267:25589–25596
   PubMed Web of Science ®Google Scholar
• Wu, C. Y., Maeda, H., Contursi, C., Ozato, K., and Seder, R. A.. 1999. Differential requirement of IFN consensus sequence binding protein for the production of IL-12 and induction of Th1-type cells in response to IFN-gamma. J. Immunol. 162:807–812
   PubMedGoogle Scholar
• Zhang, X., and Ren, R.. 1998. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92:3829–3940
   PubMed Web of Science ®Google Scholar